Therapy News and Research

RSS

Bonovo’s first PEEK lateral interbody fusion cage now available in China

Bonovo Orthopedics, Inc. announced today that it has launched the first PEEK lateral interbody fusion cage, Cross-Fuse in China.

21 Aug 2012

New attack on arthritis pain

A research team from the University of Melbourne is working on a new therapy that can potentially control the pain caused by diseases such as rheumatoid arthritis and osteoarthritis.

21 Aug 2012

Mayo Clinic receives approval for construction of new building on Phoenix campus

Mayo Clinic has been granted approval for construction of a 217,200 square-foot building on its Phoenix campus, a major expansion that will create a single-site, integrated Cancer Center. Mayo Clinic Cancer Center is the only National Cancer Institute-designated comprehensive cancer center with a multi-site, national presence, which allows us to serve a broad and diverse group of patients.

21 Aug 2012

Viewpoints: Insuring medical treatments are well researched; GOP Govs reluctance on exchanges may backfire

By 1990, many doctors were recommending hormone replacement therapy to healthy middle-aged women and P.S.A. screening for prostate cancer to older men. Both interventions had become standard medical practice. But in 2002, a randomized trial showed that preventive hormone replacement caused more problems (more heart disease and breast cancer) than it solved. ... Then, in 2009, trials showed that P.S.A. screening led to many unnecessary surgeries and had a dubious effect on prostate cancer deaths.

21 Aug 2012

Thiabendazole drug slows tumor growth and shows promise as chemotherapy for cancer

An inexpensive antifungal drug, thiabendazole, slows tumor growth and shows promise as a chemotherapy for cancer. Scientists in the College of Natural Sciences at The University of Texas at Austin made this discovery by exploiting the evolutionary relatedness of yeast, frogs, mice and humans.

21 Aug 2012

Encouraging results from Ocular Therapeutix's travoprost Phase II trial on glaucoma

Following encouraging results from Ocular Therapeutix's travoprost punctum plug feasibility study, the company is now entering a pilot Phase II clinical trial to examine a two-month sustained release drug (OTX-TP2) for the treatment of ocular hypertension and glaucoma.

21 Aug 2012

BioDiem and French partner VIVALIS a step forward in developing vaccines for diseases and related cancers

Australian infectious disease therapy and vaccine development company BioDiem Ltd (ASX: BDM) announced today successful results from two programs of work carried out by French partner VIVALIS (NYSE Euronext: VLS), confirming the ability of BioDiem’s Live Attenuated Influenza Virus (LAIV) to grow in VIVALIS’ proprietary EB66® cell line.

20 Aug 2012

PD risk factors for potential clinical screening identified

A meta-analysis has identified 19 risk factors that significantly impact a person’s risk for Parkinson’s disease and could be of potential value for clinical screening, say the authors.

20 Aug 2012

HPV genotype may alter chemoradiotherapy outcome

Human papillomavirus genotype predicts whether patients with cervical cancer will benefit from concurrent chemoradiation therapy, study findings suggest.

20 Aug 2012

Specialist referral unearths wide spectrum of adult primary immune deficiencies

The range of adult primary immune deficiencies is considerable and the majority of patients are diagnosed only after specialist referral, conclude Canadian scientists who identified two novel patient groups with humoral abnormalities.

20 Aug 2012

Physiotherapy beneficial for Parkinson’s patients

Results from a systematic review and meta-analysis published in the BMJ suggest that physiotherapy interventions benefit Parkinson’s disease (PD) patients, at least in the short term.

20 Aug 2012

Controversial activities of pro-anorexic bloggers may have benefits

A groundbreaking new research study from Indiana University suggests there may be benefits to the controversial activities of "pro-ana" bloggers, the online community for people with eating disorders.

20 Aug 2012

Anti-cancer regimens with multiple modes of action increase treatment effectiveness

Cancer may be the Harry Houdini of diseases—it often finds devious ways to escape treatment. Because cancer disables our cellular quality control mechanisms, rampant mutations that cause tumor cells to grow uncontrollably can also generate resistance to anticancer drugs. Even if 99 percent of the tumor is destroyed, that 1 percent can come roaring back. How do we knock out that 1 percent? By attacking the cancer from multiple angles, using multiple treatments and strategies.

20 Aug 2012

Happtique introduces mRx solution for electronically prescribing medical apps

Happtique, a mobile health application store and total app management solution, today announced the commencement of its pilot program of mRx, Happtique's patent-pending solution that enables physicians and other health practitioners to electronically prescribe medical, health, and fitness apps to their patients.

20 Aug 2012

Juventas commences treatment in JVS-100 Phase II STOP-HF trial for late stage heart failure

Juventas Therapeutics, a privately-held clinical-stage company developing novel regenerative therapies for treatment of cardiovascular disease, reports treating the first patient in its STOP-HF trial.

20 Aug 2012

Protein toxic to nerve cells in AD also contributes to memory loss

The underlying causes of Alzheimer's disease are not fully understood, but a good deal of evidence points to the accumulation of β-amyloid, a protein that's toxic to nerve cells. β-amyloid is formed by the activity of several enzymes, including one called BACE1. Most Alzheimer's disease patients have elevated levels of BACE1, which in turn leads to more brain-damaging β-amyloid protein.

20 Aug 2012

Abbott's XIENCE Xpedition Everolimus Eluting Coronary Stent System receives CE Mark in Europe

Abbott today announced that the XIENCE Xpedition Everolimus Eluting Coronary Stent System received CE Mark in Europe for the treatment of coronary artery disease.

20 Aug 2012

GORE Hybrid Vascular Graft receives CE Mark approval

W. L. Gore & Associates (Gore) has received CE Mark for the GORE Hybrid Vascular Graft. The graft is designed to expand treatment options for optimal outflow by maximizing the number of access sites available.

20 Aug 2012

Lilly, Boehringer Ingelheim receive FDA approval for Tradjenta sNDA to treat type 2 diabetes

Boehringer Ingelheim Pharmaceuticals, Inc. and Eli Lilly and Company today announced the U.S. Food and Drug Administration (FDA) has approved a supplemental new drug application (sNDA) for Tradjenta (linagliptin) tablets for use as add-on therapy to insulin.

18 Aug 2012

Early treatment vital for infantile hemangiomas

US research shows that infantile hemangiomas, otherwise known as “strawberry” birthmarks, grow faster and earlier than previously believed.

17 Aug 2012

Therapy News and Research

Bonovo’s first PEEK lateral interbody fusion cage now available in China

New attack on arthritis pain

Mayo Clinic receives approval for construction of new building on Phoenix campus

Viewpoints: Insuring medical treatments are well researched; GOP Govs reluctance on exchanges may backfire

Thiabendazole drug slows tumor growth and shows promise as chemotherapy for cancer

Encouraging results from Ocular Therapeutix's travoprost Phase II trial on glaucoma

BioDiem and French partner VIVALIS a step forward in developing vaccines for diseases and related cancers

PD risk factors for potential clinical screening identified

HPV genotype may alter chemoradiotherapy outcome

Specialist referral unearths wide spectrum of adult primary immune deficiencies

Physiotherapy beneficial for Parkinson’s patients

Controversial activities of pro-anorexic bloggers may have benefits

Anti-cancer regimens with multiple modes of action increase treatment effectiveness

Happtique introduces mRx solution for electronically prescribing medical apps

Juventas commences treatment in JVS-100 Phase II STOP-HF trial for late stage heart failure

Protein toxic to nerve cells in AD also contributes to memory loss

Abbott's XIENCE Xpedition Everolimus Eluting Coronary Stent System receives CE Mark in Europe

GORE Hybrid Vascular Graft receives CE Mark approval

Lilly, Boehringer Ingelheim receive FDA approval for Tradjenta sNDA to treat type 2 diabetes

Early treatment vital for infantile hemangiomas

Industry Focus eBook - Cell biology (5th edition) eBook

Evaluating new approaches for rare disease genomics

Expanding access to NMR with the Fourier 80 Duo

Advancing Intracellular Delivery with LumiPore®

Latest News